What is Synakis?
Synakis operates at the intersection of advanced materials science and regenerative medicine. The company is primarily focused on the development of SNK-125, an innovative injectable hydrogel engineered for precise ocular delivery. By prioritizing biocompatible and biodegradable solutions, Synakis addresses the unmet clinical needs associated with leading causes of blindness. The firm's market position is defined by its commitment to high-impact medical research, aiming to replace traditional, invasive surgical interventions with sophisticated, localized therapeutic delivery systems. As a pre-clinical entity, Synakis bridges the gap between academic innovation and commercial-grade medical technology, positioning itself as a key player in the evolving landscape of ophthalmic healthcare.
How much funding has Synakis raised?
Synakis has raised a total of $1.9M across 1 funding round:
Angel/Pre-Seed
$1.9M
Angel/Pre-Seed (2026): $1.9M with participation from Toronto Innovation Acceleration Partners, Ontario Centre of Innovation, and Canadian Glycomics Network
Key Investors in Synakis
Toronto Innovation Acceleration Partners
TIAP specializes in the venture building of early-stage health science technologies emerging from academic members, providing expert financial and scientific advice to de-risk innovations.
Ontario Centre of Innovation
OCI drives the commercialization of cutting-edge research across key market sectors, fostering the training of the next generation of innovators and entrepreneurs.
Canadian Glycomics Network
The Canadian Glycomics Network is a research-focused entity dedicated to developing carbohydrate-based drugs, vaccines, and diagnostics to address global health challenges.
What's next for Synakis?
Looking ahead, the strategic roadmap for Synakis involves the rigorous testing and optimization of its hydrogel delivery system. The recent capital infusion will be directed toward scaling manufacturing processes and conducting the necessary pre-clinical trials to demonstrate safety and efficacy. Furthermore, the company is expected to deepen its collaborative efforts with academic and industry partners to refine its glycomics-based research applications. As Synakis moves toward future clinical trial phases, the focus will remain on de-risking its technology and establishing a clear regulatory pathway for SNK-125. This trajectory suggests a long-term commitment to transforming the standard of care for patients with complex retinal conditions, while simultaneously building significant enterprise value for its stakeholders.
See full Synakis company page
